Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.30 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25460811 | 0.88 | SLC6A3 (0.40) | HDAC3NCOR2SLC6A3TACR1KCNN4 | |
| SCHEMBL25460807 | 0.83 | CNR2 (0.35) | HDAC3SLC6A3TACR1MAPTLTB4R | |
| SCHEMBL25460880 | 0.81 | CA12 (0.40) | SLC6A3TACR1MAPTLTB4RLTB4R2 | |
| SCHEMBL25460884 | 0.81 | MAPT (0.49) | HDAC3TACR1MAPT | |
| SCHEMBL25460797 | 0.81 | PARP1 (0.39) | HDAC3NCOR2SLC6A3KCNN4 | |
| SCHEMBL25464763 | 0.80 | CACNA1B (0.38) | — | |
| SCHEMBL25460808 | 0.79 | HCAR1 (0.44) | HDAC3NCOR2SLC6A3TACR1 | |
| SCHEMBL25460883 | 0.78 | AKR1C3 (0.39) | MAPT | |
| SCHEMBL25460768 | 0.76 | PDK1 (0.35) | — | |
| SCHEMBL30058308 | 0.75 | SLC6A3 (0.39) | HDAC3NCOR2SLC6A3TACR1KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | HDAC3 1173/4885NCOR2 338/4885SLC6A3 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.